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Abstract
Multiple myeloma (MM) patients develop osteolysis characterised by excessive osteoclastic bone destruction and lack of 
osteoblast bone formation. Pharmacological manipulation of monoacylglycerol lipase (MAGL), an enzyme responsible for the 
degradation of the endocannabinoid 2-arachidonoyl glycerol (2-AG), reduced skeletal tumour burden and osteolysis associ-
ated with osteosarcoma and advanced breast and prostate cancers. MM and hematopoietic, immune and bone marrow cells 
express high levels of type 2 cannabinoid receptor and osteoblasts secrete 2-AG. However, the efects of MAGL manipulation 
on MM have not been investigated. Here, we report that treatment of pre-osteoclasts with non-cytotoxic concentrations of 
JZL184, a veriied MAGL inhibitor, enhanced MM- and RANKL-induced osteoclast formation and size in vitro. Exposure 
of osteoblasts to JZL184 in the presence of MM cell-derived factors reduced osteoblast growth but had no efect on the abil-
ity of these cells to mature or form bone nodules. In vivo, administration of JZL184 induced a modest, yet signiicant, bone 
loss at both trabecular and cortical compartments of long bones of immunocompetent mice inoculated with the syngeneic 
5TGM1-GFP MM cells. Notably, JZL184 failed to inhibit the in vitro growth of a panel of mouse and human MM cell lines, 
or reduce tumour burden in mice. Thus, MAGL inhibitors such as JZL184 can exacerbate MM-induced bone loss.
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Abbreviations
MAGL  Monoacylglycerol lipase
MM  Multiple Myeloma
2-AG  2-Arachidonoyl glycerol
NFκB  Nuclear factor kappa-B
RANK  Receptor activator of NFκB
RANKL  RANK ligand
M-CSF  Macrophage colony stimulating factor
DMSO  Dimethyl sulfoxide
microCT  Micro-computed tomography
TRAcP  Tartrate-resistant acid phosphatase
Alk Phos  Alkaline phosphatase
ALZ  Alizarin red
GFP  Green luorescent protein
BM  Bone marrow
ANOVA  Analysis of variance
SD  Standard deviation
mm  Millimetre
MEM  Minimum essential medium
Introduction
Bone disease is a serious complication in haematological 
malignancies such as multiple myeloma (MM). Approxi-
mately, 85% of MM patients develop bone disease charac-
terised by excessive bone destruction, pain, fractures and 
lack of bone formation [1, 13, 29]. Thus, treatment strategies 
that aimed at reducing skeletal tumour burden, osteoclastic 
bone damage and bone pain would prove to be beneicial 
in terms of clinical outcomes in MM patients. Over recent 
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years, there has been increasing interest in the therapeutic 
targeting of the endogenous cannabinoid (endocannabinoid) 
system for the management of skeletal-related events and a 
number of pre-clinical studies have implicated cannabinoid 
ligands and their receptors in regulation of bone cell activ-
ity, bone remodelling and bone pain [2, 19, 22, 25, 27, 28].
MM cells express high levels of the type 2 cannabinoid 
receptor (CB2), and immune cells are known to secrete the 
endocannabinoid 2-arachidonoyl glycerol (2-AG) [2, 9, 14, 
21, 22, 43]. Thus far, limited research has been conducted 
on the therapeutic value of targeting the endocannabinoid 
system in the treatment of MM. In vitro studies have shown 
that exposure to plant-derived cannabidiol (CBD) and 
Δ9-tetrahydrocannabinol (THC), synthetic cannabinoid 
receptor agonist WIN-55,212–2 and to CB2 selective inverse 
agonists SR144528 and AM630 reduced the growth of vari-
ous mouse and human MM cell lines [4, 14, 31, 36]. In vivo, 
Barbado and colleagues have observed that administration 
of WIN-55,212–2 reduced the growth of human U226 MM 
cells in immunodeicient mice [4]. Whilst these indings sug-
gest pharmacological manipulation of cannabinoid receptors 
reduces MM cell growth, little is known about whether tar-
geting the endocannabinoid system could be of therapeutic 
value in the reduction of skeletal complications associated 
with MM.
Monoacylglycerol lipase (MAGL) is an enzyme that is 
responsible for the degradation of the endocannabinoid 
2-AG [15, 32, 40]. Previous studies have shown that 2-AG 
is secreted by bone cells at levels similar to those detected 
in the brain [2, 41–45]. Recent work carried out in our labo-
ratories has demonstrated that administration of JZL184, a 
veriied MAGL inhibitor, in mice protected against osteo-
lytic bone damage induced by solid tumours of prostate, 
breast and bone origin, namely osteosarcoma [27]. Detailed 
examination of the efects of JZL184 in healthy and can-
cer bearing mice have led us to attribute the osteoprotective 
efects of this agent to its ability to reduce the growth of solid 
tumours in the skeleton rather than inhibition of osteoclas-
tic bone resorption or stimulation of bone formation [27]. 
Intrigued by the high levels of expression of CB2 receptors 
by MM, we hypothesised that JZL184 could be of value 
in reducing MM-induced bone cell activity and osteolysis. 
Using a pharmacological approach that utilises data from 
experiments in cultures of osteoclasts, osteoblasts and MM 
cells and immunocompetent mice, we provide evidence that 
JZL184 enhanced MM-induced osteoclastogenesis in vitro 
and induced osteolytic bone loss in immunocompetent mice 
inoculated with the syngeneic murine 5TGM1-GFP cells 
without afecting tumour burden.
Materials and Methods
Reagents and Cells
The MAGL inhibitor JZL184 was purchased from Tocris 
Biosciences (Bristol, UK). Human JJN3 (DSMZ, Ger-
many) and U266 (LGC Standards, UK), murine 5TGM1 
(gift from Dr Oyajobi, University of Texas, San Antonio, 
USA), mouse RAW 264.7 macrophage and human oste-
oblast-like cells Saos-2 were originally purchased from 
ATCC (Manassas, VA). The minimum essential mediums 
(MEM) alpha(a)-MEM, delta(D)-MEM and RPMI were 
obtained from Sigma-Aldrich (Dorset, UK). Receptor acti-
vator of NFκB ligand (RANKL) was a gift from Patrick 
Mollat (Galapagos SASU, France) [17].
Osteoclast Culture
Mouse RAW 264.7 macrophage (pre-osteoclasts) were 
seeded into 96-well plates at 2 × 103 cells per well in stand-
ard D-MEM for up to 6 days in the presence and absence 
of RANKL (100 ng/ml) and/or conditioned medium from 
5TGM1-GFP MM cells (10% v/v). Mature osteoclasts and 
their precursors were identiied by staining for Tartrate-
Resistant Acid Phosphatase (TRAcP). Osteoclast area 
was visualised by phase contrast microscopy on Olym-
pus ScanR microscope, and area was quantiied by Image 
Analysis using ImageJ.
TRAcP Staining
TRAcP staining was used to identify multi-nucleated oste-
oclasts [20]. Osteoclast cultures were ixed in 4% para-
formaldehyde and incubated with naphthol-AS-BI-phos-
phate, pararosaniline and tartrate in acetate bufer (30 µM) 
at 37 °C for 45 min as previously described [20]. TRAcP 
positive cells with 3 or more nuclei were considered to be 
osteoclasts and manually counted on a Zeiss Axiovert light 
microscope using a 10 × objective lens.
Osteoblast Culture
The human osteoblast-like cells Saos-2 were seeded 
into 12-well plates at 10 × 105 cells per well in standard 
D-MEM supplemented with β-glycerol phosphate (10 μM) 
and L-ascorbic acid (50 µg/ml) for up to 10 days in the 
presence and absence of 5TGM1-GFP conditioned media 
(20% v/v). Osteoblast number, diferentiation and bone 
nodule formation were assessed by AlamarBlue assay, 
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alkaline phosphatase assay and alizarin red (ALZ) stain-
ing [39].
Alkaline Phosphatase Assay
Alkaline phosphatase activity was used to assess osteoblast 
diferentiation [39]. The human osteoblast-like cells Saos-2 
were homogenised in alkaline phosphatase lysis bufer con-
taining diethanolamine (1 M), magnesium chloride  (MgCl2, 
1 mM) Triton X100 (0.05% v/v) and cell lysate was mixed 
with an equal volume of 4-nitrophenyl phosphate disodium 
salt hexahydrate (4 mM). Absorbance was measured at 
405 nm using a SpectraMax M5® microplate reader (Molec-
ular Devices, USA).
Alizarin Red Staining
Alizarin red (ALZ) staining was used to visualise and quan-
tify bone nodule formation in osteoblast cultures [39]. The 
human osteoblast-like cells Saos-2 were ixed and immersed 
in alizarin red solution (40 mM, pH 4.2) for 20 min at room 
temperature on an orbital rotator. A destaining solution 
(10%, w/v) of cetylpyridinium chloride in sodium phosphate 
(10 mM) was added for 15 min, and absorbance (562 nm) 
was then measured using a Synergy HT plate reader (Bio 
Tek, USA).
MM Cell Culture
Mouse 5TGM1-GFP, and human U266 and JJN3 MM 
cells were cultured in standard RPMI supplemented with 
10% FCS, penicillin and streptomycin. For viability assay, 
mouse 5TGM1-GFP and human U266 and JJN3 MM cells 
were seeded into 96-well plates at 10 × 103 cells per well in 
standard D-MEM supplemented with 10% FCS, penicillin 
and streptomycin for 24 h. Cultures were then treated with 
vehicle or test compounds for the desired period. For stud-
ies involving conditioned medium, 5TGM1-GFP cells were 
allowed to grow to 80% conluency and the medium was 
refreshed with serum-free RPMI. After 16 h, the conditioned 
medium was removed and iltered (0.22 μm ilter diameter). 
Freshly prepared conditioned medium (20% v/v) was added 
to osteoclast and osteoblast cultures and their precursors in 
standard alpha-MEM supplemented [26].
AlamarBlue Assay
AlamarBlue assay was used to measure cell viability [33]. 
Cultures were treated with vehicle (0.1% v/v DMSO/PBS) 
or JZL184 (0–100 μM) for the desired period and then incu-
bated in AlamarBlue reagent (10% v/v, Thermoisher, UK) 
for 2 h. Fluorescence was measured at excitation of 530 nm 
and emission of 590 nm using a SpectraMax® M5 micro-
plate reader (Molecular Devices, USA).
Real‑Time RT‑PCR
Real-time RT-PCR (qPCR) is used to assess the expression 
of cannabinoid receptors of MAGL in bone and MM cells. 
Briely, total mRNA was extracted using RNeasy (QIA-
GEN, Germantown, MD) per the manufacturer’s protocol 
and reverse-transcribed using High-capacity cDNA reverse 
transcription kit (Applied Biosystem, Foster City, CA) on 
a T100 Thermal Cycler (Bio-Rad Laboratories, Hercules, 
CA). Quantitative PCR was performed on a CFX96 Real-
Time System (Bio-Rad Laboratories, Hercules, CA) using 
a SsoAdvanced SYBR Green Supermix (Bio-Rad Labora-
tories, Hercules, CA) and cDNA equivalent to 40 ng RNA 
in a 10 µl reaction according to the manufacturer’s instruc-
tions. For ampliication of mouse MAGL (forward primer: 
5ƍ-CAG AGA GGC CAA CCT ACT TTTC-3ƍ, reverse primer 
5ƍ-ATG CGC CCC AAG GTC ATA TTT-3ƍ); mouse CB1 
(forward primer: 5ƍ-GAC GGT GTT TGC CTT CTG TAG-3ƍ, 
reverse primer 5ƍ-GAG CAT AGA TGA TGG GGT TCA-3ƍ) and 
mouse CB2 (forward primer: 5ƍ-GGC AGT GTG ACC ATG 
ACC TT-3ƍ, reverse primer 5ƍ-GGT CAA CAG CGG TTA GCA 
G-3ƍ) were used. Relative expression was calculated using 
the comparative 2-ΔΔCt method, with actin used as a house-
keeping gene.
Animal Experiments
All procedures involving animals were approved by the UK 
Home Oice and the University of Sheield’s Animal Ethics 
Committee. Female C57BL/6KalWRij mice (8-week-old) 
received tail-vein injection of mouse 5TGM1-GFP MM cells 
 (106 cells/mouse) as previously described [36, 37]. On day 2, 
animals were divided into two groups (8 mice per group) and 
received intraperitoneal injection of either vehicle (Dime-
thyl sulfoxide (DMSO)/water, 1:10) or JZL184 (16 mg/kg, 
thrice-weekly) for 21 days. Treatment regime used was cho-
sen based on previous in vivo studies, which demonstrated 
that this agent exerted anti-tumour and anti-metastatic 
efects in mice [18, 27]. Animals were euthanized 21 days 
post injection of 5TGM1-GFP cells and bone architecture 
were assessed by micro-computed tomography (microCT) 
[5]. Tumour burden was assessed by low cytometry measur-
ing the number of green luorescent protein (GFP) positive 
5TGM1 MM cells in bone marrow, and by weighing mouse 
spleen as previously described [23, 36–38].
Micro‑Computed Tomography
Cortical and trabecular bone parameters were measured at 
the left femur (400 slices distal of the growth plate) and 
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proximal tibia (200 slices distal of the growth plate) using 
Skyscan 1172 microCT scanner (Bruker microCT, Belgium) 
set at 60 kV and 150 µA [5]. Regions of interest were recon-
structed by NRecon software and analysed using CTAn soft-
ware (Bruker microCT, Belgium) [5].
Bone Histomorphometry
Bones were ixed and embedded in methyl-methacrylate as 
previously described [12]. Osteoclast and osteoblast param-
eters were quantiied using TRAcP and toluidine blue stain-
ing, respectively [12].
Statistical Analysis
Comparison between groups was assessed by Student’s t 
test or analysis of variance (ANOVA) followed by Dunnet’s 
post hoc test (GraphPad Prism for Apple Macintosh, version 
8). A p-value of 0.05 or below was considered statistically 
signiicant.
Results
JZL184 Exerts a Biphasic Efect on RANKL 
and MM‑Induced Osteoclast Formation in Vitro
The interactions between tumour cells and the bone marrow 
environment play critical roles in the development and pro-
gression of cancer-associated bone disease including MM 
[1, 13, 29]. We have recently reported that JZL184 exerts 
a biphasic efect on osteoclastogenesis in the presence and 
absence of osteotropic prostate and breast cancer cells, as 
well as osteosarcoma cells [27]. In view of this, we irst 
assessed the efect of JZL184 (0–100 µM) on the ability 
of mouse RAW 264.7 macrophage cells (pre-osteoclasts) 
to survive and to form mature osteoclasts in the presence of 
RANKL. As shown in Fig. 1, panel A, JZL184 had no efect 
on the viability of pre-osteoclasts at a concentration range of 
3 to 30 µM. At this concentration range, JZL184 enhanced 
RANKL-induced osteoclast number in cultures of mouse 
RAW 264.7 pre-osteoclasts (Fig. 1b, p < 0.01). Of note, 
exposure to JZL184 at 100 µM inhibited the ability of RAW 
264.7 pre-osteoclasts to survive and form multi-nucleated 
osteoclasts (Fig. 1b) (p < 0.01). We attempted to study the 
efect of JZL184 on osteoclast activity by measuring the area 
of osteoclasts with 10 or more nuclei. As shown in Fig. 1c, 
exposure to JZL184 only inhibited osteoclast area at con-
centration of 100 µM (p < 0.01). Next, we went on to study 
the efects of JZL184 on MM-induced osteoclastogenesis. 
As shown in Fig. 1, panels d, e, conditioned medium (20% 
v/v) from mouse 5TGM1-GFP MM cells markedly increased 
osteoclast number in RANKL-stimulated RAW 264.7 
macrophages and this efect was signiicantly enhanced by 
JZL184 (1–10 µM) (p < 0.01). In addition, JZL184 had no 
efects on MM-induced growth of pre-osteoclast at these 
concentrations (Fig. 1f).
JZL184 Reduced Osteoblast Growth in the Presence 
of MM‑Derived Factors
JZL184 inhibited osteoblastic bone formation in mouse 
models of osteosarcoma [27]. Here, we irst exposed the 
human osteoblast-like cells Saos-2 to a range of concentra-
tions of JZL184 (0–100 µM), and we observed a signiicant 
inhibition of cell number within 3 days of exposure to a 
concentration 100 µM (Fig. S1). In view of this, we went on 
to test the efects of this agent on osteoblast proliferation, 
diferentiation and bone nodule formation in the presence 
and absence of MM-derived factors at a concentration of 
10 µM or lower. These experiments showed that conditioned 
medium (20% v/v) from mouse 5TGM1-GFP MM cells 
markedly increased the number of the human osteoblast-like 
cells Saos-2 after 5 and 7 days, and these efects were not 
signiicantly afected by exposure to JZL184 at concentra-
tions up to 10 µM (Fig. 2a, left and middle panels). After 
10 days, the efect of MM-derived factors on Saos-2 number 
was diminished, and JZL184 signiicantly reduced Saos-2 
number at 10 µM (Fig. 2a, right panel) (p < 0.05). To study 
the efect of JZL184 on osteoblast maturation, we examined 
the efects of JZL184 (1 µM) on alkaline phosphatase activ-
ity (osteoblast diferentiation marker) and bone nodule for-
mation after 5 and 7 days of culture in the presence of MM 
conditioned medium. The treatment period and concentra-
tion were chosen on the basis that JZL184 exerted no detri-
mental efects on cell number or viability after 7 and 10 days 
of continuous exposure (Fig. 2a). As shown in Fig. 2b, con-
ditioned medium (20% v/v) from mouse 5TGM1-GFP MM 
cells reduced alkaline phosphatase activity, indicative of 
reduced osteoblast diferentiation, and this was not afected 
by JZL184 (1 µM) (p < 0.05). Interestingly, neither 5TGM1-
GFP conditioned medium (20% v/v) nor JZL184 (1 µM) 
treatment afected the ability of the human osteoblast-like 
Saos-2 to form nodule after 5 and 7 days at the concentration 
tested (Fig. 2c). Representative photomicrographs of bone 
nodule formation from the experiments described are shown 
in Fig. 2, panel d.
JZL184 Exerted a Biphasic Efect on MM Cell Number 
in Vitro
Previous studies have shown that JZL184 reduced skel-
etal growth of osteosarcoma and osteotropic cancer cells 
of breast and prostate origin in vitro and in vivo [27]. In 
this study, we assessed the efects of JZL184 on the in vitro 
growth of a panel of mouse and human MM cell lines at 
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concentrations up to 100 µM. As shown in Fig. 3, JZL184 
(0–30 μM) exerted a modest inhibitory efect on the growth 
of mouse 5TGM1-GFP and human U266 and JJN3 MM cells 
(Fig. 3, panels a to c), a concentration range that caused a 
signiicant efect on osteoclastogenesis and osteoblast dif-
ferentiation. At 100 µM, however, JZL184 signiicantly 
enhanced the growth of 5TGM1-GFP (Fig. 3a) and U266 
(Fig. 3b) cells, and exerted a non-signiicant increase in the 
number of JJN3 cells (Fig. 3c).
JZL184 Had No Efect Tumour Burden in Mice 
Bearing MM
Next, we conirmed that the syngeneic MM cells 5TGM1-
GFP express MAGL (Fig. S2, panel a), and went on to test 
the efects of JZL184 (16 mg/kg, thrice-weekly) on tumour 
burden in C57BL/6KalWRij female mice inoculated with 
5TGM1-GFP MM cells (Fig. 4a). The main advantage of 
this model is it allowed us to examine the efects of JZL184 
on the progression of MM in immunocompetent mice. The 
dosing regime of JZL184 have been chosen on the basis of 
previous mouse studies that have shown it reduced cancer-
induced bone disease [27] and reduced tumour growth and 
metastasis [15, 34, 35]. As shown in Fig. 4b, administration 
of JZL184 had no efect on skeletal tumour burden as evi-
dent by the number of GFP positive MM cells in the bone 
marrow (Fig. 4b, left) and tumour size (Fig. 4b, right), when 
compared to vehicle (0.01% DMSO) treated mice. Similarly, 
JZL184 had no efect on tumour burden in the spleen when 
compared to vehicle-treated mice (Fig. 4c).
Fig. 1  JZL184 enhances RANKL and MM-induced osteoclast for-
mation. a In  vitro cell viability and survival of mouse RAW 264.7 
macrophage (pre-osteoclasts) treated with vehicle or JZL184 
(0–100 μM) for 6 days, as assessed by AlamarBlue assay. b In vitro 
number of multi-nucleated osteoclasts with 3 or more nuclei in cul-
tures of RANKL (100 ng/ml)-stimulated mouse RAW 264.7 mature 
osteoclasts treated with vehicle or JZL184 (0–100 μM) for 6 days as 
visualised by TRAcP staining. c Area of TRAcP positive osteoclasts 
in cultures of RANKL (100  ng/ml)-stimulated osteoclasts in mouse 
RAW 264.7 cultures treated with vehicle or JZL184 (0 –100 μM) for 
6 days as measured by ImageJ. d In vitro multi-nucleated osteoclast 
number in cultures of RANKL-stimulated mouse RAW 264.7 pre-
osteoclasts treated with vehicle or JZL184 (0–10 μM) for 7 days in 
the presence and absence of conditioned medium from 5TGM1-GFP 
MM cells (CM, 10% v/v), as visualised by TRAcP staining. e Rep-
resentative photomicrographs of multi-nucleated osteoclasts from the 
experiment described in panel d. f In vitro viability and survival of 
osteoclast precursors in the experiment described in panels d and e, 
as assessed by AlamarBlue assay. Values are mean ± SD: **p < 0.01 
from vehicle; # p < 0.05 from other JZL184 treated cultures; $ 
p < 0.05 from vehicle plus 5TGM1-GFP conditioned medium
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JZL184 Reduced Trabecular and Cortical Bone 
Volume in Mice Bearing MM
Detailed microCT analysis of the trabecular and cortical 
bone compartments of the long bones of the mice from the 
experiment described in Fig. 4a showed that administration 
of JZL184 (16 mg/kg, thrice-weekly) in immunocompetent 
mice bearing 5TGM1-GFP MM cells caused signiicant loss 
of total bone volume (Fig. 4d and e). Analysis of the trabecu-
lar compartment of these mice revealed signiicant reduction 
in bone volume (Tb.BV/TV, Fig. 5a) that is characterised 
by signiicant reduction in trabecular thickness (Tb.Th, 
Fig. 5b) and reduced trabecular connectivity as measured 
by the increase in trabecular pattern factor (Tb.Pf, Fig. 5d). 
Interestingly, we detected signiicant loss in trabecular num-
ber in the tibia—but not the femur—of these mice (p < 0.05, 
Tb.N, Fig. 5c). Additionally, we observed no changes in tra-
becular separation (Tb.Sp, Fig. 5e) or trabecular porosity 
(Tb.Po(tot), Fig. 5f). Representative microCT images of tra-
becular bone from tibiae and femurs of the mice described 
are shown in Fig. 5, panel g. In the cortical compartment, 
treatment with JZL184 reduced cortical bone volume (Ct.
BV, Fig. 6a), cortical thickness (Ct.Th, Fig. 6b), cortical 
diameter (Ct.Dm, Fig. 6c) and medullary cavity diameter 
(CtmedCVdem, Fig. 6d) in both tibia and femur of mice 
bearing the mouse 5TGM1-GFP MM cells. Furthermore, 
JZL184 increased cortical porosity (Ct.Po(tot), Fig. 6e) at 
the tibia—but not at the femur—of these mice. Representa-
tive microCT images of cortical bone from tibiae and femurs 
of the mice described are shown in Fig. 6, panel f. Collec-
tively, these results conirm that JZL184 induces bone loss in 
the MM mouse model described. Surprisingly, histological 
and histomorphometrical analysis of the tibial metaphysis 
revealed that JZL184 exerted no signiicant efects on the 
number of osteoclasts in both trabecular and cortical com-
partments (Fig. 7a). Histological and histomorphometrical 
analysis of the tibial metaphysis revealed a non-signiicant 
reduction in osteoblast number in the trabecular—but not 
cortical—compartment (Fig. 7a, p < 0.05). Analysis of oste-
oclast number in these sites showed that JZL184 exerted 
no signiicant efect (Fig.7b and c). Representative photo-
micrographs of histological sections from the experiment 
described are shown in Fig. 7, panel c.
JZL184 Had No Efect on Body and Spleen Weight 
in Mice Bearing MM
Body weight is an important determinant of bone mass 
and previous studies have shown that manipulation of the 
endocannabinoid system afects appetite and body weight 
[7, 8, 10]. Here, we report that administration of JZL184 
(16 mg/kg, thrice-weekly) had no efect on body (Fig. 8a) 
or spleen (Fig. 8b) weight in immunocompetent mice bear-
ing the mouse 5TGM1-GFP MM cells when compared to 
vehicle-treated mice.
Discussion
MM cells express the CB2 receptor, and immune and bone 
cells secrete the endocannabinoid 2-AG [2, 9, 14, 21, 22, 
43]. Previous studies by Nomura et al. and our laboratories 
have shown that knockdown and pharmacological inhibition 
of MAGL—the enzyme that is responsible for the degrada-
tion of 2-AG [15, 32, 40]—inhibited the in vitro and in vivo 
growth of primary bone sarcoma and reduced the metastatic 
spread and bone damage associated with prostate and breast 
cancer [27, 32, 34]. In the present study, we report the efects 
of pharmacological manipulation of MAGL on the initiation 
and progression of tumour burden and bone disease associ-
ated with MM. Using a combination of in vitro studies in 
cultures of MM and bone cells and the murine 5TGM1-GFP 
model of MM, we observed that 5TGM1-GFP MM cells 
express MAGL but the exposure of these cells to the veri-
ied MAGL inhibitor JZL184 had no efect on their ability 
to grow in the bone marrow or spleen of immunocompetent 
mice. This inding contradicted previous published stud-
ies by our laboratories and others [27, 32, 34] that showed 
JZL184 reduced tumour growth in mouse models of osteo-
sarcoma and prostate and breast cancers. Whist we cannot 
readily explain this, it is important to note that MM cells 
express MAGL and high levels of CB2 receptors [2, 9, 14, 
21, 22, 43] and our present data showed that exposure to 
JZL184 at 100 µM signiicantly enhanced the in vitro growth 
of mouse 5TGM1 MM cells. Thus, we cannot exclude the 
possibility that MAGL and 2-AG expressed by these cells—
as well as immune and/or bone cells—have no role in the 
tumour burden in the model described. Moreover, the anti-
tumour efects of JZL184 that we and others have previ-
ously reported were observed in models of solid tumours 
[27, 32, 34]. Therefore, the fact that hematopoietic tumours 
Fig. 2  JZL184 reduced osteoblast growth in the presence of multi-
ple myeloma-derived factors. a In vitro osteoblast viability in human 
osteoblast-like Saos-2 cultures exposed to standard or conditioned 
medium from 5TGM1-GFP MM cells (CM, 20% v/v) in the presence 
or absence of JZL184 (0–10  µM) for 5, 7 and 10  days, as assessed 
by AlamarBlue assay. b, c In vitro osteoblast diferentiation (b) and 
bone nodule formation (c) in human osteoblast-like Saos-2 cultures 
exposed to standard or conditioned medium from 5TGM1-GFP MM 
cells (CM, 20% v/v) in the presence or absence of JZL184 (1  µM) 
for 5 and 7  days. Osteoblast viability (a), diferentiation (b) and 
bone nodule formation (c) were assessed by AlamarBlue, Alkaline 
phosphatase and Alizarin Red assays, respectively. d Representative 
photomicrographs of bone nodule formation from the experiment 
described in panel c. Values are mean  ± SD. *p< 0.05 and **p < 
0.01 from vehicle without conditioned medium; $ p < 0.05 from vehi-
cle plus 5TGM1-GFP conditioned medium
◂
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including MM cells are anatomically diferent from solid 
tumours, could provide a plausible explanation for the lack 
of anti-tumour efect by JZL184 in our model. For example, 
hypoxia plays diferent roles in the progression of MM and 
solid tumours [16], and there is evidence to suggest that 
hypoxia-induced inhibition of the endocannabinoid system 
enhances glioblastoma cell growth [16]. Thus, it is likely 
that diferent hypoxic conditions in mice bearing MM and 
solid tumours might have afected the level tumour- and/or 
host-derived endocannabinoids by JZL184. Therefore, fur-
ther in vivo studies are needed.
Osteolysis plays an important role in the pathogenesis 
of MM-associated bone disease [1, 13, 29]. In view of this, 
we examined the efects of JZL184 on osteolytic bone dam-
age in mice bearing the syngeneic 5TGM1-GFP cells. This 
experiment revealed that administration of JZL184 induced 
a modest, yet signiicant, loss in total bone volume in the 
long bones of mice. Detailed microCT analysis showed that 
the bone-wasting efect of this agent was evident at both 
trabecular and cortical bone compartments of the tibia and 
femur of mice bearing 5TGM1-GFP MM cells. These ind-
ings are in broad agreement with our previous results that 
showed JZL184 induced bone loss in non-cancer bearing 
immunocompetent mice [27]. To gain an insight in the 
efects of JZL184 on bone cell activity in the presence and 
absence of MM cells, we irst tested the efects of JZL184 
on osteoclast formation and size in the presence of factors 
derived from 5TGM1-GFP MM cells. Our studies showed 
that JZL184 enhanced both osteoclast number and area 
induced by RANKL and conditioned medium from 5TGM1-
GFP MM cells, indicative of stimulatory efects on osteo-
clast formation and size. It is important to note here that the 
cultures of osteoclasts and their precursor cells were exposed 
to JZL184 at concentrations that failed to afect cell viabil-
ity or survival—thus excluding any cytotoxic efects. These 
results are consistent with our previous indings that showed 
that JZL184—and the endocannabinoid 2-AG—enhanced 
osteoclast formation at concentrations that failed to sup-
press M-CSF dependent bone marrow pre-osteoclasts [27]. 
Quantitative assessment of cannabinoid receptor expression 
showed that the mouse RAW 264.7 pre-osteoclasts used in 
the present studies express the cannabinoid receptor CB2 
(Fig. S2, panel B), further implicating the endocannabinoid 
systems in these efects. In contrast to these indings and our 
present in vitro data in osteoclast cultures, JZL184 had no 
efect in osteoclast number in trabecular bones of mice bear-
ing the syngeneic 5TGM1 MM cells. Of note, the mice in 
the present experiment sufered signiicant loss in trabecular 
bone and thus only small number of osteoclasts were pre-
sent. In the cortical compartment, we observed no signiicant 
efect in osteoclast number but we noted a non-signiicant 
reduction in osteoblast number.
Osteoblasts produce the endocannabinoid 2-AG and we 
reported that JZL184 exerted a paradoxical efect on osteo-
blast diferentiation and activity in the presence and absence 
of osteosarcoma and osteotropic prostate and breast cancer 
Fig. 3  JZL184 exerted a biphasic efect on MM cell number in vitro. 
a–c In vitro viability of mouse 5TGM1-GFP (a) and human U266 (b) 
and JJN3 (c) MM cells exposed to vehicle (0.01% DMSO) or JZL184 
(0–100  μM) for 48  h. Cell viability was assessed by AlamarBlue 
assay. Values are mean ± SD. *p < 0.05
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cells. At a concentration range that JZL184 enhanced osteo-
clast formation in vitro, it had no efect on the ability of the 
human osteoblast-like Saos-2 to grow, mature and form bone 
nodules in the presence of factors derived from 5TGM1-
GFP MM cells.
Similarly, JZL184 failed to afect osteoblast number and 
activity in mice bearing 5TGM1-GFP MM cells. Interest-
ingly, in vitro exposure to JZL184 at 100 µM for 3 days and 
10 µM for 10 days reduced the number of the human oste-
oblast-like cells Saos-2. Whist it is reasonable to attribute 
this efect to cytotoxicity, Saos-2 cells secrete 2-AG in cul-
ture [27], thus it is possible that Saos-2-derived 2-AG—in 
cooperation with a cocktail of other mediators and signal-
ling pathways [6, 11, 24, 30]—might have contributed to 
these efects. The support for this hypothesis comes from the 
observation that administration of JZL184 caused a non-sig-
niicant reduction in osteoblast number in the trabecular—
but not cortical—compartment of mice bearing MM cells.
Collectively, the results presented in this study extend 
our and others previous findings on the role of the 
Fig. 4  JZL184 induces bone loss without afecting tumour growth 
in mice bearing MM. a Graphic representation of tail-vein injection 
of mouse 5TGM1-GFP MM cells  (106 cells/mouse) into 8-week-old 
adult C57BL/6KalWRij mice treated with vehicle (0.01% DMSO) 
(n = 8 per group) or JZL184 (16  mg/kg, thrice-weekly) (n = 8) for 
21  days. b Skeletal tumour burden as assessed by low cytometry 
(left) and histological (right) analysis of GFP positive 5TGM1 MM 
cells in bone marrow (n = 8 per group), and presented as percentage 
of total cell count. c Tumour burden in spleen presented as percent-
age of spleen to body weight (n = 8 per group). d Total bone volume 
(BV, tot) at the tibia and femur of mice (n = 8 per group) from the 
experiment described in panels a–c, as assessed by microCT. e Repre-
sentative photomicrographs of microCT scan of the tibial metaphysis 
of mice from the experiment described in panels a–d at low and high 
power (scale bar = 1  mm). Values are mean ± SD; *p < 0.05 versus 
vehicle
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Fig. 5  JZL184 induces trabecular bone loss in mice bearing MM. 
Trabecular bone parameters at the tibial and femoral metaphysis of 
8 weeks old adult C57BL/6KalWRij mice treated with vehicle (0.01% 
DMSO) (n = 8) or JZL184 (16  mg/kg, thrice-weekly) (n = 8 per 
group) for 21  days post injection of mouse 5TGM1-GFP MM cells 
 (106 cells/mouse). Trabecular bone volume (BV/TV, panel a), tra-
becular thickness (Tb.Th, panel b), trabecular number (Tb.N, panel 
c), trabecular pattern factor (Tb. Pf, panel d), trabecular separation 
(Tb.S, panel e) and trabecular porosity (Ct.Po(tot), panel f) were 
assessed by microCT. g Representative microCT images of trabecu-
lar bone from tibiae and femur of mice described in panels a–f (scale 
bar = 1 mm). Values are mean ± SD; *p < 0.05 and **p < 0.01 versus 
vehicle
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endocannabinoid system in the skeleton [3, 19, 27, 28], 
and support the hypothesis that MAGL inhibitors such as 
JZL184 are inefective in reducing neither tumour growth 
nor osteolytic bone damage caused by haematological malig-
nancies such as MM. The ability of JZL184 to enhance oste-
oclast number and reduce osteoblast number in vitro provide 
a tentative mechanism for the signiicant loss in trabecular 
and cortical bone observed in mice bearing 5TGM1-GFP 
MM cells. When combined with previous studies that 
showed MAGL inhibitors such as JZL184 induce bone loss 
in healthy mice but reduce bone damage by inhibiting the 
growth of solid tumours [27], our current data reveal a com-
plex role of MAGL and the body’s own cannabinoid system 
in the regulation of bone remodelling in solid [27, 32, 34] 
versus haematological ‘liquid’ malignancies such as MM.
Fig. 6  JZL184 induces cortical bone loss in mice bearing MM. Corti-
cal bone parameters at the tibial and femoral metaphysis of 8-week-
old adult C57BL/6KalWRij mice treated with vehicle (0.01% DMSO) 
(n = 8) or JZL184 (16 mg/kg, thrice-weekly) (n = 8) for 21 days post 
injection of mouse 5TGM1-GFP MM cells  (106 cells/mouse). Cor-
tical bone volume (Ct.BV, panel a), cortical thickness (Ct.Th, panel 
b), cortical diameter (Ct.Dm, panel c), medullary cavity diameter 
(CtmedCVdem, panel d) and cortical porosity (Ct.Po(tot), panel e) 
were assessed by microCT. f Representative microCT images of cor-
tical bone from tibiae and femur of the mice described in panels a–e 
(scale bar = 1 mm). Values are mean ± SD; *p < 0.05 versus vehicle
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Fig. 7  Efects of JZL184 on osteoblast and osteoclast number in mice 
bearing MM. In vivo percentage of osteoblasts (a, Ob.S/BS, %) and 
osteoclasts (b, Oc.S/BS, %) from the cortical and trabecular compart-
ments of the tibial metaphysis of 8-week-old adult C57BL/6KalWRij 
mice treated with vehicle (0.01% DMSO) (n = 8) or JZL184 (16 mg/
kg, thrice-weekly) (n = 8) for 21  days post injection of mouse 
5TGM1-GFP MM cells  (106 cells/mouse). c Representative photo-
micrographs of histological sections from the experiment described. 
Scale bar = 50 µm. Values are mean ± SD; ns denotes not statistically 
signiicant
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